Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Venous Thromboembolism 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 72Cisplatin 57Cetuximab 38Fluorouracil 25Nivolumab 21Radiotherapy 20Carboplatin 19Paclitaxel 14Docetaxel 11Cyclophosphamide 9Gefitinib 8fludarabine 7durvalumab 7zalutumumab 6atezolizumab 6Drug Therapy 6Bleomycin 6epacadostat 5cemiplimab 5Radiotherapy, Intensity-Modulated 5Pemetrexed 5Ipilimumab 5Gemcitabine 5Afatinib 5spartalizumab 4Standard of Care 4Radiation 4Injections 4Immune Checkpoint Inhibitors 4Fibroblast Growth Factor 7 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Head and Neck Neoplasms × ALT-836 × Clear all
NCT01325558 2016-07-15

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Altor BioScience

Phase 1 Completed
30 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡